RUNX3 Promotes the Tumorigenic Phenotype in KGN, a Human Granulosa Cell Tumor-Derived Cell Line.
COV434
KGN
RUNX3
cyclin D2
granulosa cell tumor of the ovary
p27Kip1
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
15 Jul 2019
15 Jul 2019
Historique:
received:
16
05
2019
revised:
02
07
2019
accepted:
12
07
2019
entrez:
18
7
2019
pubmed:
18
7
2019
medline:
18
12
2019
Statut:
epublish
Résumé
Granulosa cell tumors of the ovary (GCT) are the predominant type of ovarian sex cord/stromal tumor. Although prognosis is generally favorable, the outcome for advanced and recurrent GCT is poor. A better understanding of the molecular pathogenesis of GCT is critical to developing effective therapeutic strategies. Here we have examined the potential role of the runt-related transcription factor RUNX3. There are only two GCT cell lines available. While RUNX3 is silenced in the GCT cell line KGN cells, it is highly expressed in another GCT cell line, COV434 cells. Re-expression of RUNX3 promotes proliferation, anchorage-independent growth, and motility in KGN cells in vitro and tumor formation in mice in vivo. Furthermore, expression of a dominant negative form of RUNX3 decreases proliferation of COV434 cells. To address a potential mechanism of action, we examined expression of cyclin D2 and the CDK inhibitor p27
Identifiants
pubmed: 31311113
pii: ijms20143471
doi: 10.3390/ijms20143471
pmc: PMC6678151
pii:
doi:
Substances chimiques
Core Binding Factor Alpha 3 Subunit
0
Cyclin D3
0
Runx3 protein, human
0
Cyclin-Dependent Kinase Inhibitor p27
147604-94-2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIH HHS
ID : HD085994
Pays : United States
Organisme : Alberta Cancer Foundation
ID : N/A
Organisme : Granulosa Cell Tumour Research Foundation
ID : N/A
Organisme : Women and Children's Health Research Institute
ID : N/A
Organisme : P30 Cancer Center Support Grant
ID : NCI-CA125123
Organisme : NCI NIH HHS
ID : R01 CA138628
Pays : United States
Organisme : NIH HHS
ID : CA138628
Pays : United States
Organisme : NICHD NIH HHS
ID : R01 HD085994
Pays : United States
Références
Mol Hum Reprod. 2000 Feb;6(2):146-53
pubmed: 10655456
Endocrinology. 2001 Jan;142(1):437-45
pubmed: 11145608
J Biol Chem. 2001 Nov 16;276(46):43004-9
pubmed: 11562367
J Biol Chem. 2004 Jul 9;279(28):29409-17
pubmed: 15138260
Mol Cancer. 2004 Dec 01;3:33
pubmed: 15574200
Cancer Res. 2005 Sep 1;65(17):7743-50
pubmed: 16140942
Mol Endocrinol. 2006 Sep;20(9):2156-72
pubmed: 16675540
Mol Cell Biol. 2006 Jun;26(12):4474-88
pubmed: 16738314
Oncogene. 2006 Dec 7;25(58):7646-9
pubmed: 16767156
J Clin Oncol. 2007 Jul 10;25(20):2944-51
pubmed: 17617526
Gynecol Oncol. 2009 Feb;112(2):325-30
pubmed: 18937968
BMC Cancer. 2008 Nov 04;8:319
pubmed: 18980698
Endocrinology. 2009 Jul;150(7):3291-300
pubmed: 19342459
N Engl J Med. 2009 Jun 25;360(26):2719-29
pubmed: 19516027
Cancer Res. 2009 Oct 15;69(20):8111-9
pubmed: 19808967
Oncogene. 2010 Feb 11;29(6):811-21
pubmed: 19915614
J Biol Chem. 2010 Mar 26;285(13):10122-9
pubmed: 20100835
Mol Endocrinol. 2010 Apr;24(4):846-58
pubmed: 20197312
Biochem Biophys Res Commun. 2010 Oct 22;401(3):376-81
pubmed: 20854793
Gynecol Oncol. 2011 Aug;122(2):410-7
pubmed: 21612813
Oncogene. 2012 Jan 26;31(4):527-34
pubmed: 21706051
Endocr Rev. 2012 Feb;33(1):109-44
pubmed: 22240241
Mol Cell Endocrinol. 2012 Oct 15;362(1-2):165-75
pubmed: 22713854
PLoS One. 2012;7(11):e48299
pubmed: 23155381
Cell Cycle. 2013 Mar 15;12(6):972-86
pubmed: 23442798
Br J Cancer. 2013 Jul 9;109(1):29-34
pubmed: 23756859
J Cell Physiol. 2013 Dec;228(12):2350-64
pubmed: 23813439
J Clin Invest. 2013 Sep;123(9):3876-88
pubmed: 23979164
PLoS One. 2013 Oct 04;8(10):e74384
pubmed: 24124450
Biochem Biophys Res Commun. 2014 Jan 10;443(2):537-42
pubmed: 24332943
Gynecol Oncol. 2014 May;133(2):382-7
pubmed: 24342437
Nat Commun. 2014;5:2936
pubmed: 24390485
PLoS One. 2014 Jan 09;9(1):e85545
pubmed: 24416423
Bull Cancer. 2014 Jan 1;101(1):93-101
pubmed: 24445864
Curr Opin Oncol. 2014 Sep;26(5):536-41
pubmed: 25024052
Cancer Lett. 2014 Nov 1;354(1):107-14
pubmed: 25128652
Cell Signal. 2014 Dec;26(12):2793-800
pubmed: 25193116
Nat Rev Cancer. 2015 Feb;15(2):81-95
pubmed: 25592647
Gynecol Oncol. 2015 Sep;138(3):647-55
pubmed: 26186909
Int J Biochem Cell Biol. 2015 Nov;68:9-14
pubmed: 26279144
Mol Endocrinol. 2016 Jul;30(7):733-47
pubmed: 27176614
J Reprod Dev. 2016 Oct 18;62(5):479-486
pubmed: 27301496
Gynecol Oncol. 2017 Mar;144(3):621-630
pubmed: 28104295
Ann Med. 2017 Aug;49(5):435-447
pubmed: 28276867
Mol Cancer Ther. 2017 May;16(5):850-860
pubmed: 28292935
PLoS One. 2017 Jun 8;12(6):e0178989
pubmed: 28594898
Gynecol Oncol. 2018 May;149(2):350-360
pubmed: 29551565
Endocrinology. 2018 May 1;159(5):2094-2109
pubmed: 29554271
Eur J Obstet Gynecol Reprod Biol. 2018 Jun;225:57-61
pubmed: 29665458
Cell Tissue Res. 2019 Mar;375(3):743-754
pubmed: 30377784
Virology. 1993 May;194(1):314-31
pubmed: 8386878
Mol Endocrinol. 1998 Jul;12(7):924-40
pubmed: 9658398